Pricing Log in Create free account

Capricor Therapeutics, Inc. (CAPR) vs CorMedix Inc (CRMD)

Capricor Therapeutics, Inc. and CorMedix Inc are both Biotechnology companies. Capricor Therapeutics, Inc. is the larger, with a market value of $479.1M against $433.4M — 1.1× the size. Capricor Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; CorMedix Inc trades at 2.3×. CorMedix Inc grew revenue faster over the last twelve months: 280.5% against −11.6%. CorMedix Inc has the higher net margin (40.5% vs 0.00%) and the higher return on invested capital (38.8% vs −1,019.7%). Across the 19 metrics below, CorMedix Inc leads on 16 and Capricor Therapeutics, Inc. on 3.

Valuation

Metric CAPR CRMD Biotechnology median
P/E n/m 2.28 10.64
P/S 21.17 0.93 9.59
P/B 1.92 0.94 2.15
Price to free cash flow 3.60 1.72 26.07
EV/EBITDA n/m 1.26 0.65
EV/Sales 11.13 0.69 9.45
Earnings yield (30.10%) 43.82% (34.69%)
Free cash flow yield 27.76% 58.04% (24.02%)

Profitability

Metric CAPR CRMD Biotechnology median
Gross margin 100.00% 82.78% 65.59%
Operating margin 0.00% 46.95% 0.00%
Net margin 0.00% 40.49% 0.00%
Free cash flow margin 0.00% 54.17% 0.00%
Return on equity (73.70%) 54.93% (51.96%)
Return on assets (51.53%) 32.36% (46.06%)
Return on invested capital (1,019.73%) 38.84% 0.00%

Growth

Metric CAPR CRMD Biotechnology median
Revenue growth (TTM) (11.55%) 280.50% 4.59%
EPS growth (last fiscal year) (96.52%) 780.00% 29.88%
Revenue growth, 5-year CAGR 85.83% 305.79% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CAPR CRMD Biotechnology median
Debt to equity 0.00 0.32 0.00
Current ratio 7.35 2.56 4.86
Net debt to EBITDA 2.99 (0.02) 1.01

Dividend

Metric CAPR CRMD Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric CAPR CRMD Biotechnology median
Market cap 479.07m 433.37m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack